Drugs Made In America Acquisition (DMAAU) Enterprise Value (2024 - 2025)

Drugs Made In America Acquisition (DMAAU) reported Enterprise Value of -$6137.0 for Q4 2025, down 354.26% on a YoY basis from $2413.7 in Q4 2024, and down 755.93% quarter-over-quarter from -$717.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAU) Enterprise Value (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Enterprise Value for 2 years, with the latest figure at -$6137.0 in Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 354.26% year-over-year to -$6137.0; the trailing twelve-month figure through Dec 2025 stood at -$6137.0 (down 354.26% YoY), and the FY2025 full-year result was -$6137.0, down 354.26% from the prior year.
  • Enterprise Value for Q4 2025 stood at -$6137.0, down from -$717.0 in the prior quarter.
  • The five-year high for Enterprise Value was -$717.0 in Q3 2025, with the low at -$6137.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Enterprise Value (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -1.47 Mn
2 Berto Acquisition 312.46 Mn 312.46 Mn - -209,016.00
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -28,828.00
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - -112,660.00
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -167,798.00
6 WEN Acquisition 309.15 Mn 309.15 Mn - -553,972.00
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - -521,352.00
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - -56,403.00
9 BTC Development 262.16 Mn 262.16 Mn - -1.45 Mn
10 Drugs Made In America Acquisition - - - -6,137.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -6,137.00
Sep 30, 2025 -717.00
Jun 30, 2025 -822.00
Mar 31, 2025 -923.00
Dec 31, 2024 -1,351.00